Search

Your search keyword '"Collet, Jp"' showing total 720 results
Start Over Author "Collet, Jp"
720 results on '"Collet, Jp"'

2. Theoretical domains framework to assess barriers to change for planning health care quality interventions: a systematic literature review

Author

Mosavianpour M, Sarmast HH, Kissoon N, and Collet JP

Subjects
Theoretical Domains Framework, TDF, practice change, healthcare quality improvement, barriers, Medicine (General), R5-920
Abstract

Mirkaber Mosavianpour,1–3 Hamideh Helen Sarmast,2,3 Niranjan Kissoon,1–3 Jean-Paul Collet1–3 1Department of Pediatrics, Faculty of Medicine, University of British Columbia, 2British Columbia Children’s Hospital, 3Child and Family Research Institute, Vancouver, BC, Canada Background: Theoretical domains framework (TDF) provides an integrative model for assessing barriers to behavioral changes in order to suggest interventions for improvement in behavior and ultimately outcomes. However, there are other tools that are used to assess barriers.Objective: The objective of this study is to determine the degree of concordance between domains and constructs identified in two versions of the TDF including original (2005) and refined version (2012) and independent studies of other tools.Methods: We searched six databases for articles that studied barriers to health-related behavior changes of health care professionals or the general public. We reviewed quantitative papers published in English which included their questionnaires in the article. A table including the TDF domains of both original and refined versions and related constructs was developed to serve as a reference to describe the barriers assessed in the independent studies; descriptive statistics were used to express the results.Results: Out of 552 papers retrieved, 50 were eligible to review. The barrier domains explored in these articles belonged to two to eleven domains of the refined TDF. Eighteen articles (36%) used constructs outside of the refined version. The spectrum of barrier constructs of the original TDF was broader and could meet the domains studied in 48 studies (96%). Barriers in domains of “environmental context and resources”, “beliefs about consequences”, and “social influences” were the most frequently explored in 42 (84%), 37 (74%), and 33 (66%) of the 50 articles, respectively.Conclusion: Both refined and original TDFs cataloged barriers measured by the other studies that did not use TDF as their framework. However, the original version of TDF explored a broader spectrum of barriers than the refined version. From this perspective, the original version of the TDF seems to be a more comprehensive tool for assessing barriers in practice. Keywords: theoretical domains framework, TDF, practice change, health care quality improvement, barriers

Published
2016

3. Lymphocytic Choriomeningitis Virus Infection, Australia

Author

Caly, L, Porter, AF, Chua, J, Collet, JP, Druce, JD, Catton, MG, Duchene, S, Caly, L, Porter, AF, Chua, J, Collet, JP, Druce, JD, Catton, MG, and Duchene, S

Abstract

During a mouse plague in early 2021, a farmer from New South Wales, Australia, sought treatment for aseptic meningitis and was subsequently diagnosed with locally acquired lymphocytic choriomeningitis virus infection. Whole-genome sequencing identified a divergent and geographically distinct lymphocytic choriomeningitis virus strain compared with other published sequences.

Published
2022

4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic : part 1: epidemiology, pathophysiology, and diagnosis The Task Force for the management of COVID-19 of the European Society of Cardiology

Author

Baigent, C, Windecker, S, Andreini, D, Arbelo, E, Barbato, E, Bartorelli, AL, Baumbach, A, Behr, ER, Berti, S, Bueno, H, Capodanno, D, Cappato, R, Chieffo, A, Collet, JP, Cuisset, T, de Simone, G, Delgado, V, Dendale, P, Dudek, D, Edvardsen, T, Elvan, A, Gonzalez-Juanatey, JR, Gori, M, Grobbee, D, Guzik, TJ, Halvorsen, S, Haude, M, Heidbuchel, H, Hindricks, G, Ibanez, B, Karam, N, Katus, H, Klok, FA, Konstantinides, SV, Landmesser, U, Leclercq, C, Leonardi, S, Lettino, M, Marenzi, G, Mauri, J, Metra, M, Morici, N, Mueller, C, Petronio, AS, Polovina, MM, Potpara, T, Praz, F, Prendergast, B, Prescott, E, Price, S, Pruszczyk, P, Rodriguez-Leor, O, Roffi, M, Romaguera, R, Rosenkranz, S, Sarkozy, A, Scherrenberg, M, Seferovic, P, Senni, M, Spera, FR, Stefanini, G, Thiele, H, Tomasoni, D, Torracca, L, Touyz, RM, Wilde, AA, Williams, B, and Task Force for the management of COVID-19 of the European Society of Cardiology

Subjects
Myocarditis, Myocardial injury, Non-invasive imaging, ACE2, COVID-19, Human medicine, Arrhythmias, Cardiogenic shock, Biomarkers
Abstract

Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. [GRAPHICS] .

Published
2022

5. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Author

Knuuti, Juhani, Wijns, William, Saraste, Antti, Capodanno, Davide, Barbato, Emanuele, Funck-Brentano, Christian, Prescott, Eva, Storey, Robert F, Deaton, Christi, Cuisset, Thomas, Agewall, Stefan, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Gersh, Bernard J, Svitil, Pavel, Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Valgimigli, Marco, Achenbach, Stephan, Bax, Jeroen J, Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Leclercq C, Lewis BS, Merkely B, Mueller C, Petersen S, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B, Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Knuuti, Juhani, Wijns, William, Saraste, Antti, Capodanno, Davide, Barbato, Emanuele, Funck-Brentano, Christian, Prescott, Eva, Storey, Robert F, Deaton, Christi, Cuisset, Thoma, Agewall, Stefan, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Gersh, Bernard J, Svitil, Pavel, Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Valgimigli, Marco, Achenbach, Stephan, Bax, Jeroen J, Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B, Clinical sciences, Cardio-vascular diseases, Cardiology, Knuuti, Juhani [0000-0003-3156-9593], Apollo - University of Cambridge Repository, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), University of Zurich, Knuuti, J., Wijns, W., Achenbach, S., Agewall, S., Barbato, E., Bax, J. J., Capodanno, D., Cuisset, T., Deaton, C., Dickstein, K., Edvardsen, T., Escaned, J., Funck-Brentano, C., Gersh, B. J., Gilard, M., Hasdai, D., Hatala, R., Mahfoud, F., Masip, J., Muneretto, C., Prescott, E., Saraste, A., Storey, R. F., Svitil, P., Valgimigli, M., Windecker, S., Aboyans, V., Baigent, C., Collet, J. -P., Dean, V., Delgado, V., Fitzsimons, D., Gale, C. P., Grobbee, D. E., Halvorsen, S., Hindricks, G., Iung, B., Juni, P., Katus, H. A., Landmesser, U., Leclercq, C., Lettino, M., Lewis, B. S., Merkely, B., Mueller, C., Petersen, S., Petronio, A. S., Richter, D. J., Roffi, M., Shlyakhto, E., Simpson, I. A., Sousa-Uva, M., Touyz, R. M., Benkhedda, S., Metzler, B., Sujayeva, V., Cosyns, B., Kusljugic, Z., Velchev, V., Panayi, G., Kala, P., Haahr-Pedersen, S. A., Kabil, H., Ainla, T., Kaukonen, T., Cayla, G., Pagava, Z., Woehrle, J., Kanakakis, J., Toth, K., Gudnason, T., Peace, A., Aronson, D., Riccio, C., Elezi, S., Mirrakhimov, E., Hansone, S., Sarkis, A., Babarskiene, R., Beissel, J., Cassar Maempel, A. J., Revenco, V., de Grooth, G. J., Pejkov, H., Juliebo, V., Lipiec, P., Santos, J., Chioncel, O., Duplyakov, D., Bertelli, L., Dikic, A. D., Studencan, M., Bunc, M., Alfonso, F., Back, M., Zellweger, M., Addad, F., Yildirir, A., Sirenko, Y., and Clapp, B.

Subjects
anti-ischaemic drug, chronic coronary syndromes, medicine.medical_treatment, [SDV]Life Sciences [q-bio], lipid-lowering drugs, Diagnostic Techniques, Cardiovascular, antithrombotic therapy, Disease, 030204 cardiovascular system & hematology, Guideline, Coronary artery disease, 0302 clinical medicine, Disease management (health), Societies, Medical, ComputingMilieux_MISCELLANEOUS, chronic coronary syndrome, angina pectori, Disease Management, food and beverages, imaging, risk assessment, Syndrome, 3. Good health, Natural history, Europe, Cardiology, Cardiology and Cardiovascular Medicine, coronary artery disease, medicine.medical_specialty, lifestyle modifications, anti-ischaemic drugs, Ischemia, 610 Medicine & health, vasospastic angina, Guidelines, Revascularization, diagnostic testing, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, angina pectoris, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Journal Article, Humans, business.industry, screening, fungi, 030229 sport sciences, medicine.disease, lipid-lowering drug, Angina pectoris, Anti-ischaemic drugs, Antithrombotic therapy, Chronic coronary syndromes, Diagnostic testing, Imaging, Lifestyle modifications, Lipid-lowering drugs, Microvascular angina, Myocardial ischaemia, Myocardial revascularization, Risk assessment, Screening, Vasospastic angina, myocardial ischaemia, myocardial revascularization, Heart failure, microvascular angina, Chronic Disease, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, lifestyle modification, Coronary Artery Disease/diagnosis, business, Fibrinolytic agent
Abstract

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

Published
2019

6. 2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk (vol 290, pg 140, 2019)

Author

Mach, F, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, Chapman, MJ, De Backer, GG, Ference, BA, Graham, IM, Halliday, A, Mihaylova, B, Pedersen, TR, Riccardi, G, Sabatine, MS, Taskinen, MR, Tokgozoglu, L, Wiklund, O, Nibouche, D, Zelveian, PH, Siostrzonek, P, Najafov, R, van de Borne, P, Pojskic, B, Postadzhiyan, A, Kypris, L, Spinar, J, Larsen, ML, Eldin, HS, Viigimaa, M, Strandberg, TE, Ferrieres, J, Agladze, R, Laufs, U, Rallidis, L, Bajnok, L, Gudjonsson, T, Maher, V, Henkin, Y, Gulizia, MM, Mussagaliyeva, A, Bajraktari, G, Kerimkulova, A, Latkovskis, G, Hamoui, O, Slapikas, R, Visser, L, Dingli, P, Ivanov, V, Boskovic, A, Nazzi, M, Visseren, F, Mitevska, I, Retterstol, K, Jankowski, P, Fontes-Carvalho, R, Gaita, D, Ezhov, M, Foscoli, M, Giga, V, Pella, D, Fras, Z, de Isla, LP, Hagstrom, E, Lehmann, R, Abid, L, Ozdogan, O, Mitchenko, O, Patel, RS, Windecker, S, Aboyans, V, Baigent, C, Collet, JP, Dean, V, Delgado, V, Fitzsimons, D, Gale, CP, Grobbee, D, Halvorsen, S, Hindricks, G, Iung, B, Juni, P, Katus, HA, Landmesser, U, Leclercq, C, Lettino, M, Lewis, BS, Merkely, B, Mueller, C, Petersen, S, Petronio, AS, Richter, DJ, Roffi, M, Shlyakhto, E, Simpson, IA, Sousa-Uva, M, and Touyz, RM

Published
2020

7. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Author

Mach, F, Baigent, C, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, Chapman, MJ, De Backer, GG, Delgado, V, Ference, BA, Graham, IM, Halliday, A, Landmesser, U, Mihaylova, B, Pedersen, TR, Riccardi, G, Richter, DJ, Sabatine, MS, Taskinen, MR, Tokgozoglu, L, Wiklund, O, Mueller, C, Drexel, H, Aboyans, V, Corsini, A, Doehner, W, Farnier, M, Gigante, B, Kayikcioglu, M, Krstacic, G, Lambrinou, E, Lewis, BS, Masip, J, Moulin, P, Petersen, S, Petronio, AS, Piepoli, MF, Pinto, X, Raber, L, Ray, KK, Reiner, Z, Riesen, WF, Roffi, M, Schmid, JP, Shlyakhto, E, Simpson, IA, Stroes, E, Sudano, I, Tselepis, AD, Viigimaa, M, Vindis, C, Vonbank, A, Vrablik, M, Vrsalovic, M, Gomez, JLZ, Collet, JP, European Soc Cardiology, and European Atherosclerosis Soc

Subjects
high-density lipoproteins, lipoprotein remnants, dyslipidaemias, cholesterol, treatment (drugs), very low-density lipoproteins, Guidelines, treatment (lifestyle), treatment (adherence), lipoprotein(a), total cardiovascular risk, low-density lipoproteins, familial hypercholesterolaemia, apolipoprotein B, triglycerides
Published
2020

8. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Author

Valgimigli, M, Bueno, H, Byrne, RA, Collet, JP, Costa, F, Jeppsson, A, Juni, P, Kastrati, A, Kolh, P, Mauri, L, Montalescot, G, Neumann, FJ, Petricevic, M, Roffi, M, Steg, PG, Windecker, S, Zamorano, JL, Levine, GN, Badimon, L, Vranckx, P, Agewall, S, Andreotti, F, Antman, E, Barbato, E, Bassand, JP, Bugiardini, R, Cikirikcioglu, M, Cuisset, T, De Bonis, M, Delgado, V, Fitzsimons, D, Oliver, G, Galie, N, Gilard, M, Hamm, CW, Ibanez, B, Iung, B, James, S, Knuuti, J, Landmesser, U, Leclercq, C, Lettino, M, Lip, G, Piepoli, MF, Pierard, L, Schwerzmann, M, Sechtem, U, Simpson, IA, Uva, MS, Stabile, E, Storey, RF, Tendera, M, Van De Werf, F, Verheugt, F, Aboyans, V, Task Force Dual Antiplatelet Ther, and European Asso Cardio-Thoracic Surg

Subjects
Ticagrelor, Stable angina, Aspirin, Stent thrombosis, Revascularization, Bleeding, Coronary artery bypass grafting, Guidelines, Acute coronary syndromes, Recommendation, Coronary artery disease, Clopidogrel, Percutaneous coronary intervention, Myocardial infarction, Non-cardiac surgery, Dual antiplatelet therapy, Stents, Stable coronary artery disease, Oral anticoagulant, DAPT score, Triple therapy, Prasugrel, Drug-eluting stents, Risk stratification, PRECISE-DAPT score
Published
2018

10. Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation

Author

Nijenhuis VJ, Bennaghmouch N, Hassell M, Baan J, Jr., van Kuijk JP, Agostoni P, van 't Hof A, Kievit PC, Veenstra L, van der Harst P, van den Heuvel AF, den Heijer P, Kelder JC, Deneer VH, van der Kley F, Onorati F, Collet JP, Maisano F, Latib A, Huber K, Stella PR, Ten Berg JM, Nijenhuis, Vj, Bennaghmouch, N, Hassell, M, Baan, J, J, R., van Kuijk, Jp, Agostoni, P, van 't Hof, A, Kievit, Pc, Veenstra, L, van der Harst, P, van den Heuvel, Af, den Heijer, P, Kelder, Jc, Deneer, Vh, van der Kley, F, Onorati, F, Collet, Jp, Maisano, F, Latib, A, Huber, K, Stella, Pr, and Ten Berg, Jm

Published
2016

11. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy

Author

Deaton, C, Simpson, Ia, Aboyans, V, Agewall, S, Barbato, E, Calda, P, Coca, A, Coman, Im, De Backer, J, Delgado, V, Di Salvo, G, Fitzsimmons, S, Fitzsimons, D, Garbi, M, Gevaert, S, Hindricks, G, Jondeau, G, Kluin, J, Lionis, C, Mcdonagh, Ta, Meier, P, Moons, P, Pantazis, A, Piepoli, Mf, Rocca, Bianca, Roffi, M, Rosenkranz, S, Sarkozy, A, Shlyakhto, E, Silversides, Ck, Sliwa, K, Sousa-Uva, M, Tamargo, J, Thorne, S, Van de Velde, M, Williams, B, Zamorano, Jl, Windecker, S, Bueno, H, Collet, Jp, Dean, V, Gaemperli, O, Iung, B, Jüni, P, Katus, Ha, Knuuti, J, Lancellotti, P, Leclercq, C, Ponikowski, P, Richter, Dj, Hammoudi, N, Piruzyan, A, Mascherbauer, J, Samadov, F, Prystrom, A, Pasquet, A, Caluk, J, Gotcheva, N, Skoric, B, Heracleous, H, Vejlstrup, N, Maser, M, Kaaja, Rj, Srbinovska-Kostovska, E, Mounier-Vehier, C, Vakhtangadze, T, Rybak, K, Giannakoulas, G, Kiss, Rg, Thrainsdottir, I, Erwin, Rj, Porter, A, Geraci, G, Ibrahimi, P, Lunegova, O, Mintale, I, Kadri, Z, Benlamin, H, Barysiene, J, Banu, Ca, Caruana, M, Gratii, C, Haddour, L, Bouma, Bj, Estensen, Me, Hoffman, P, Petris, Ao, Moiseeva, O, Bertelli, L, Tesic, Bv, Dubrava, J, Koželj, M, Prieto-Arévalo, R, Furenäs, E, Schwerzmann, M, Mourali, M, Ozer, N, Mitchenko, O, Nelson-Piercy, C., Rocca B (ORCID:0000-0001-8304-6423), Deaton, C, Simpson, Ia, Aboyans, V, Agewall, S, Barbato, E, Calda, P, Coca, A, Coman, Im, De Backer, J, Delgado, V, Di Salvo, G, Fitzsimmons, S, Fitzsimons, D, Garbi, M, Gevaert, S, Hindricks, G, Jondeau, G, Kluin, J, Lionis, C, Mcdonagh, Ta, Meier, P, Moons, P, Pantazis, A, Piepoli, Mf, Rocca, Bianca, Roffi, M, Rosenkranz, S, Sarkozy, A, Shlyakhto, E, Silversides, Ck, Sliwa, K, Sousa-Uva, M, Tamargo, J, Thorne, S, Van de Velde, M, Williams, B, Zamorano, Jl, Windecker, S, Bueno, H, Collet, Jp, Dean, V, Gaemperli, O, Iung, B, Jüni, P, Katus, Ha, Knuuti, J, Lancellotti, P, Leclercq, C, Ponikowski, P, Richter, Dj, Hammoudi, N, Piruzyan, A, Mascherbauer, J, Samadov, F, Prystrom, A, Pasquet, A, Caluk, J, Gotcheva, N, Skoric, B, Heracleous, H, Vejlstrup, N, Maser, M, Kaaja, Rj, Srbinovska-Kostovska, E, Mounier-Vehier, C, Vakhtangadze, T, Rybak, K, Giannakoulas, G, Kiss, Rg, Thrainsdottir, I, Erwin, Rj, Porter, A, Geraci, G, Ibrahimi, P, Lunegova, O, Mintale, I, Kadri, Z, Benlamin, H, Barysiene, J, Banu, Ca, Caruana, M, Gratii, C, Haddour, L, Bouma, Bj, Estensen, Me, Hoffman, P, Petris, Ao, Moiseeva, O, Bertelli, L, Tesic, Bv, Dubrava, J, Koželj, M, Prieto-Arévalo, R, Furenäs, E, Schwerzmann, M, Mourali, M, Ozer, N, Mitchenko, O, Nelson-Piercy, C., and Rocca B (ORCID:0000-0001-8304-6423)

Abstract

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

Published
2018

12. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)

Author

Lip, GYH, Collet, JP, de Caterina, R, Fauchier, L, Lane, DA, Larsen, TB, Marin, F, Morais, J, Narasimhan, C, Olshansky, B, Pierard, L, Potpara, T, Sarrafzadegan, N, Sliwa, K, Varela, G, Vilahur, G, Weiss, T, Boriani, G, Rocca, B, Gorenek, B, Savelieva, I, Sticherling, C, Kudaiberdieva, G, Chao, TF, Violi, F, Nair, M, Zimerman, L, Piccini, J, Storey, R, Halvorsen, S, Gorog, D, Rubboli, A, Chin, A, Scott-Millar, R, and ESC Sci Document Grp

Subjects
Stroke, Mechanical prosthetic heart valves, Anticoagulation, Mitral stenosis, Vitamin K antagonists, Pregnancy, Stroke prevention, Thrombo-embolism, Non-vitamin K antagonist oral anticoagulants, Atrial fibrillation, Valvular heart disease
Abstract

Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with valvular heart disease (VHD) is also common. However, management strategies for this group of patients have been less informed by randomized trials, which have largely focused on 'non-valvular AF' patients. Thrombo-embolic risk also varies according to valve lesion and may also be associated with CHA(2)DS(2)VASc score risk factor components, rather than only the valve disease being causal. Given marked heterogeneity in the definition of valvular and non-valvular AF and variable management strategies, including non-vitamin K antagonist oral anticoagulants (NOACs) in patients with VHD other than prosthetic heart valves or haemodynamically significant mitral valve disease, there is a need to provide expert recommendations for professionals participating in the care of patients presenting with AF and associated VHD. To address this topic, a Task Force was convened by the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Thrombosis, with representation from the ESC Working Group on Valvular Heart Disease, Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca gamma Electrofisiologia (SOLEACE) with the remit to comprehensively review the published evidence, and to publish a joint consensus document on the management of patients with AF and associated VHD, with up-to-date consensus recommendations for clinical practice for different forms of VHD. This consensus document proposes that the term 'valvular AF' is outdated and given that any definition ultimately relates to the evaluated practical use of oral anticoagulation (OAC) type, we propose a functional Evaluated Heartvalves, Rheumatic or Artificial (EHRA) categorization in relation to the type of OAC use in patients with AF, as follows: (i) EHRA Type 1 VHD, which refers to AF patients with 'VHD needing therapy with a Vitamin K antagonist (VKA); and (ii) EHRA Type 2 VHD, which refers to AF patients with 'VHD needing therapy with a VKA or a Non-VKA oral anticoagulant (NOAC)', also taking into consideration CHA(2)DS(2)VASc score risk factor components. This consensus document also summarizes current developments in the field, and provides general recommendations for the management of these patients based on the principles of evidence-based medicine.

Published
2017

14. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction The ATLANTIC-H-24 Analysis

Author

Montalescot, G, van't Hof, AW, Bolognese, L, Cantor, WJ, Cequier, A, Chettibi, M, Collet, JP, Goodman, SG, Hammett, CJ, Huber, K, Janzon, M, Lapostolle, F, Lassen, JF, Licour, M, Merkely, B, Salhi, N, Silvain, J, Storey, RF, ten Berg, JM, Tsatsaris, A, Zeymer, U, Vicaut, E, Hamm, CW, Peñaranda, A.S., and Carson, Andy

Subjects
myocardial infarction, stents, platelets, thrombosis, reperfusion
Abstract

OBJECTIVES The aim of this landmark exploratory analysis, ATLANTIC-H-24, was to evaluate the effects of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention (PCI) in the ATLANTIC (Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery) study. BACKGROUND The ATLANTIC trial in patients with ongoing ST-segment elevation myocardial infarction showed that pre-hospital ticagrelor was safe but did not improve pre-PCI coronary reperfusion compared with in-hospital ticagrelor. We hypothesized that the effect of pre-hospital ticagrelor may not have manifested until after PCI due to the rapid transfer time (31 min). METHODS The ATLANTIC-H-24 analysis included 1,629 patients who underwent PCI, evaluating platelet reactivity, Thrombolysis In Myocardial Infarction flow grade 3, >= 70% ST-segment elevation resolution, and clinical endpoints over the first 24 h. RESULTS Following PCI, largest between-group differences in platelet reactivity occurred at 1 to 6 h; coronary reperfusion rates numerically favored pre-hospital ticagrelor, and the degree of ST-segment elevation resolution was significantly greater in the pre-hospital group (median, 75.0% vs. 71.4%; p = 0.049). At 24 h, the composite ischemic endpoint was lower with pre-hospital ticagrelor (10.4% vs. 13.7%; p = 0.039), as were individual endpoints of definite stent thrombosis (p = 0.0078) and myocardial infarction (p = 0.031). All endpoints except death (1.1% vs. 0.2%; p = 0.048) favored pre-hospital ticagrelor, with no differences in bleeding events. CONCLUSIONS The effects of pre-hospital ticagrelor became apparent after PCI, with numerical differences in platelet reactivity and immediate post-PCI reperfusion, associated with reductions in ischemic endpoints, over the first 24 h, whereas there was a small excess of mortality. (Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery [ATLANTIC, NCT01347580]) (C) 2016 by the American College of Cardiology Foundation.

Published
2016

15. P2Y12 inhibitors

Author

Collet Jp and Montalescot G

Subjects
medicine.medical_specialty, Acute coronary syndrome, Prasugrel, Thienopyridine, business.industry, Hematology, Bioinformatics, medicine.disease, Clopidogrel, Endocrinology, Adenine nucleotide, Internal medicine, Thienopyridines, medicine, Platelet aggregation inhibitor, Ticlopidine, business, medicine.drug
Abstract

SummaryThe P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin. Three generationsof thienopyridines, ticlopidine, clopidogrel, and prasugrel have proven efficacy in the prevention of ischemic vascular events but with increased bleeding. The concept of individualized tailored therapy has recently emerged with the discovery of the diminished effect of some thienopyridine among carriers of the loss-of-function cytochrome (CYP) P4502C19*2 variant. Non-thienopyridine P2Y12 antagonists have also recently demonstrated that these benefits are not limited to one class of agents or may be generalizable to reversible antagonists of this receptor. Future rational use of these agents will require attention to disease and patient features to strike the optimal balance of benefit to risk.

Published
2009

17. Painful Neuropathic Disorders: An Analysis of the RéGie De L’Assurance Maladie du QuéBec Database

Author

Collet Jp, Allan Gordon, Manon Choinière, Jean-Eric Tarride, Dominique Dion, and Jean Lachaine

Subjects
Male, medicine.medical_specialty, Databases, Factual, MEDLINE, Comorbidity, Health services, Drug Utilization Review, Assurance maladie, Health care, medicine, Humans, Medication Errors, Intensive care medicine, Psychiatry, lcsh:R5-920, Analgesics, business.industry, Quebec, Health Services, Middle Aged, medicine.disease, Anesthesiology and Pain Medicine, Neurology, Costs and Cost Analysis, Neuralgia, Original Article, Female, lcsh:Medicine (General), business
Abstract

BACKGROUND/OBJECTIVE: Painful neuropathic disorders (PNDs) refer to neurological disorders involving nerves in which pain is a predominant symptom. In most cases, PNDs involve the peripheral nerves. Treatment of PNDs is likely to use large health care resources. However, little is known about the economic burden of PNDs in Canada.METHOD: The present study was performed using data from a random sample of patients covered by the Régie de l’Assurance Maladie du Quebec drug plan. Subjects with a diagnosis of a peripheral PND were identified. Comorbidities, pain-related medication use and resource utilization were compared between PND patients and control patients without PNDs matched for age and sex in a 1:1 ratio.RESULTS: A total of 4912 patients with PNDs were identified. A higher level of comorbidities was found in the PND group (Von Korff chronic disease score 3.91 versus 2.54; P2; PCONCLUSIONS: PNDs are associated with a higher level of comorbidities, higher medical resources utilization and higher health care costs than non-PND conditions.

Published
2007

18. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Working Group of the European Society of Cardiology (ESC) to conduct affairs in acute coronary syndromes without ST segment elevation of persistent

Author

Roffi, M, Patrono, C, Collet, JP, Mueller, C, Valgimigli, Marco, Andreotti, F, Bax, JJ, Borger, MA, Brotons, C, Chew, DP, Gencer, B, Hasenfuss, G, Kjeldsen, K, Lancellotti, P, Landmesser, U, Mehilli, J, Mukherjee, D, Storey, RF, Windecker, S, and Cardiology

Published
2015

19. The economic burden of neuropathic pain in Canada

Author

Catherine Rousseau, Manon Choinière, Jean-Eric Tarride, Allan Gordon, and Collet Jp

Subjects
medicine.medical_specialty, business.industry, Health Policy, fungi, Primary care, medicine.disease, Indirect costs, Peripheral neuropathy, Neuropathic pain, Health care, Neuralgia, Physical therapy, Medicine, Observational study, Medical prescription, business
Abstract

SummaryThe management of neuropathic pain (NeP) is a major healthcare consideration from a treatment perspective. The objective of this research was to quantify the economic burden of NeP in Canada. A cross-sectional observational study was conducted at primary care sites across three Canadian provinces among patients suffering from NeP associated with diabetic peripheral neuropathy, post-herpetic neuralgia, cervical radiculopathy and post-operative neuropathy. Economic burden of illness data were collected through an investigator chart review and patient self-administered questionnaires to capture NeP resource utilisation and productivity losses. Primary care physicians enrolled 126 patients with a mean age of 58.7 years (standard deviation (sd) 13.5 years). The 3-month direct costs of NeP were estimated at $1,137 (sd $1,346) in 2003, of which 77% was attributable to NeP prescriptions, over-the-counter medications and visits to other healthcare providers. Indirect costs were estimated at $1,430 (sd $2,02...

Published
2006

20. 2014 ESC/EACTS Guidelines on myocardial revascularization

Author

Kolh, P, Alfonso, F, Collet, JP, Cremer, J, Falk, V, Filippatos, G, Hamm, C, Head, SJ, Juni, P, Kappetein, AP, Kastrati, A, Landmesser, U, Laufer, G, Neumann, FJ, Richter, DJ, Schauerte, P, Stefanini, GG, Taggart, DP, Torracca, L, Valgimigli, M, Witkowski, A, Baumgartner, H, Bax, JJ, Bueno, H, Dean, V, Erol, C, Fagard, R, Ferrari, R, Hoes, AW, Knuuti, J, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, MF, Ponikowski, P, Sirnes, PA, Tamargo, JL, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Uva, MS, Achenbach, S, Pepper, J, Anyanwu, A, Badimon, L, Bauersachs, J, Baumbach, A, Beygui, F, Bonaros, N, De Carlo, M, Deaton, C, Dobrev, D, Dunning, J, Eeckhout, E, Gielen, S, Hasdai, D, Kirchhof, P, Luckraz, H, Mahrholdt, H, Montalescot, G, Paparella, D, Rastan, AJ, Sanmartin, M, Sergeant, P, Silber, S, Tamargo, J, ten Berg, J, Thiele, H, van Geuns, RJ, Wagner, HO, Wassmann, S, Wendler, O, and Zamorano, JL

Subjects
Stable angina, Medical therapy, Revascularization, Coronary artery bypass grafting, Acute coronary syndromes, Guidelines, Myocardial ischaemia, Recommendation, EuroSCORE, Coronary artery disease, Percutaneous coronary intervention, SYNTAX score, ST-segment elevation myocardial infarction, Myocardial infarction, Bare-metal stents, Myocardial revascularization, Heart Team, Stents, Stable coronary artery disease, Drug-eluting stents, Risk stratification
Published
2014

21. 2014 ESC/EACTS Guidelines on myocardial revascularization

Author

Windecker, S, Alfonso, F, Collet, JP, Cremer, J, Falk, V, Filippatos, G, Hamm, C, Head, SJ, Juni, P, Kappetein, AP, Kastrati, A, Landmesser, U, Laufer, G, Neumann, FJ, Richter, DJ, Schauerte, P, Uva, MS, Stefanini, GG, Taggart, DP, Torracca, L, Valgimigli, M, Wijns, W, Witkowski, A, Zamorano, JL, Achenbach, S, Baumgartner, H, Bax, JJ, Bueno, H, Dean, V, Deaton, C, Erol, C, Fagard, R, Ferrari, R, Hasdai, D, Hoes, AW, Kirchhof, P, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, N, Piepoli, MF, Ponikowski, P, Sirnes, PA, Tamargo, JL, Tendera, M, Torbicki, A, Pepper, J, Anyanwum, A, Badimon, L, Bauersachs, J, Baumbach, A, Beygui, F, Bonaros, N, De Carlo, M, Dobrev, D, Dunning, J, Eeckhout, E, Gielen, S, Luckraz, H, Mahrholdt, H, Montalescot, G, Paparella, D, Rastan, AJ, Sanmartin, M, Sergeant, P, Silber, S, Tamargo, J, ten Berg, J, Thiele, H, van Geuns, RJ, Wagner, HO, Wassmann, S, Wendler, O, Weidinger, F, Ibrahimov, F, Legrand, V, Terzic, I, Postadzhiyan, A, Skoric, B, Georgiou, GM, Zelizko, M, Junker, A, Eha, J, Romppanen, H, Bonnet, JL, Aladashvili, A, Hambrecht, R, Becker, D, Gudnason, T, Segev, A, Bugiardini, R, Sakhov, O, Mirrakhimov, A, Pereira, B, Felice, H, Trovik, T, Dudek, D, Pereira, H, Nedeljkovic, MA, Hudec, M, Cequier, A, Erlinge, D, Roffi, M, Kedev, S, Addad, F, Yildirir, A, and Davies, J

Subjects
Stable angina, Medical therapy, Revascularization, Coronary artery bypass grafting, Acute coronary syndromes, Guidelines, Myocardial ischaemia, Recommendation, EuroSCORE, Coronary artery disease, Percutaneous coronary intervention, SYNTAX score, ST-segment elevation myocardial infarction, Myocardial infarction, Bare-metal stents, Myocardial revascularization, Heart Team, Stents, Stable coronary artery disease, Drug-eluting stents, Risk stratification
Published
2014

22. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Author

Steg, Pg, James, Sk, Atar, D, Badano, Lp, Lundqvist, Cb, Borger, Ma, Di Mario, C, Dickstein, K, Ducrocq, G, Fernandez Aviles, F, Gershlick, Ah, Giannuzzi, P, Halvorsen, S, Huber, K, Juni, P, Kastrati, A, Knuuti, J, Lenzen, Mj, Mahaffey, Kw, Valgimigli, M, Van't Hof, A, Widimsky, P, Zahger, D, ESC Committee for Practice Guidelines, Bax, Jj, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewers, Astin, F, Aström Olsson, K, Budaj, A, Clemmensen, P, Collet, Jp, Fox, Ka, Fuat, A, Gustiene, O, Hamm, Cw, Kala, P, Lancellotti, P, Maggioni, Ap, Merkely, B, Neumann, Fj, Piepoli, Mf, Van de Werf, F, Verheugt, F, Wallentin, L., Steg, P, James, S, Atar, D, Badano, L, Lundqvist, C, Borger, M, Di Mario, C, Dickstein, K, Ducrocq, G, Fernandez-Aviles, F, Gershlick, A, Giannuzzi, P, Halvorsen, S, Huber, K, Juni, P, Kastrati, A, Knuuti, J, Lenzen, M, Mahaffey, K, Valgimigli, M, Van'T Hof, A, Widimsky, P, Zahger, D, Bax, J, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Funck-Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, B, Reiner, Z, Sechtem, U, Sirnes, P, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Astin, F, Astrom-Olsson, K, Budaj, A, Clemmensen, P, Collet, J, Fox, K, Fuat, A, Gustiene, O, Hamm, C, Kala, P, Lancellotti, P, Maggioni, A, Merkely, B, Neumann, F, Piepoli, M, Van De Werf, F, Verheugt, F, and Wallentin, L

Subjects
Emergency Medical Services, Biomedical Research, General Practice, Myocardial Infarction, Guideline, Anxiety, ST-segment elevation, Electrocardiography, Myocardial infarction, Coronary Artery Bypass, 610 Medicine & health, Fibrinolytic Agent, Cardiovascular diseases [NCEBP 14], Secondary prevention, General Medicine, Reperfusion therapy, Antifibrinolytic Agents, Exercise Therapy, Hospitalization, cardiovascular system, Cardiology, Acute coronary syndromes Ischaemic heart disease, Cardiomyopathies, Cardiology and Cardiovascular Medicine, Ticagrelor, Human, medicine.drug, Acute coronary syndrome, medicine.medical_specialty, Cardiotonic Agents, Pain, Myocardial Reperfusion, Acute myocardial infarction, Guidelines, Antifibrinolytic Agent, Risk Assessment, Time-to-Treatment, Percutaneous Coronary Intervention, Fibrinolytic Agents, Internal medicine, medicine, Humans, Cardiotonic Agent, Hemodynamic, cardiovascular diseases, Emergency Treatment, Cardiomyopathie, Heart Failure, Cardiac Imaging Technique, Management of acute coronary syndrome, Emergency Medical Service, business.industry, Coronary Artery Bypa, Platelet Aggregation Inhibitor, Hemodynamics, Arrhythmias, Cardiac, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, Long-Term Care, Primary percutaneous coronary intervention Antithrombotic therapy, Cardiac Imaging Techniques, Dyspnea, Hyperglycemia, Door-to-balloon, Myocardial infarction complications, Myocardial infarction diagnosis, business, Risk Reduction Behavior, Platelet Aggregation Inhibitors, Out-of-Hospital Cardiac Arrest, Forecasting
Abstract

ACE : angiotensin-converting enzyme ACS : acute coronary syndrome ADP : adenosine diphosphate AF : atrial fibrillation AMI : acute myocardial infarction AV : atrioventricular AIDA-4 : Abciximab Intracoronary vs. intravenously Drug Application APACHE II : Acute Physiology Aand Chronic

Published
2012

23. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Author

Hamm, Cw, Bassand, Jp, Agewall, S, Bax, J, Boersma, E, Bueno, H, Caso, P, Dudek, D, Gielen, S, Huber, K, Ohman, M, Petrie, Mc, Sonntag, F, Uva, Ms, Storey, Rf, Wijns, W, Zahger, D, ESC Committee for Practice Guidelines, Bax, Jj, Auricchio, A, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Poldermans, D, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewers, Achenbach, S, Badimon, L, Bertrand, M, Bøtker, He, Collet, Jp, Crea, F, Danchin, N, Falk, E, Goudevenos, J, Gulba, D, Hambrecht, R, Herrmann, J, Kastrati, A, Kjeldsen, K, Kristensen, Sd, Lancellotti, P, Mehilli, J, Merkely, B, Montalescot, G, Neumann, Fj, Neyses, L, Perk, J, Roffi, M, Romeo, F, Ruda, M, Swahn, E, Valgimigli, M, Vrints, Cj, Widimsky, P., and Neyses, Ludwig [collaborator]

Subjects
unstable angina, Male, Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors, Diabetic Cardiomyopathies, Platelet Aggregation Inhibitors/therapeutic use, heparin, Diagnostic Imaging/methods, Myocardial Revascularization, ST segment, Myocardial Revascularization/methods, guidelines, Angioplasty, Balloon, Coronary, Biological Markers/blood, Coronary Artery Bypass, Aged, 80 and over, Evidence-Based Medicine, diabetes, bivalirudin, troponin, Age Factors, Diabetic Cardiomyopathies/diagnosis/therapy, angioplasty, enoxaparin, Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine], Prognosis, Angioplasty, Balloon, Coronary/methods, Anticoagulants/therapeutic use, Cardiology, Biological Markers, Female, Cardiology and Cardiovascular Medicine, Physical Examination/methods, Diagnostic Imaging, medicine.medical_specialty, Cardiotonic Agents, aspirin, non-ST-elevation myocardial infarction, Hemorrhage, Platelet Glycoprotein GPIIb-IIIa Complex, Risk Assessment, Acute Coronary Syndrome/diagnosis/etiology/*therapy, acute coronary syndrome, European Society of Cardiology, ticagrelor, Diagnosis, Differential, Internal medicine, chest pain unit, medicine, Humans, In patient, Hemorrhage/etiology, Acute Coronary Syndrome, Physical Examination, Aged, clopidogrel, Management of acute coronary syndrome, Task force, business.industry, Acute Coronary Syndrome/diagnosis/etiology/therapy, fondaparinux, Elevation, Anticoagulants, Long-Term Care, Cardiotonic Agents/therapeutic use, prasugrel, bypass surgery, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, stent, Cardiovascular & respiratory systems [D03] [Human health sciences], business, Biomarkers, Biomarkers/blood, Platelet Aggregation Inhibitors
Abstract

Eur Heart J

Published
2011

24. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers

Author

Daniel Floret, Jean-Jacques Chomel, T Ducruet, Haggerty J, Collet Jp, F. Dürr, and Michael S. Kramer

Subjects
Microbiology (medical), Recurrent infections, medicine.medical_specialty, Innate immune system, business.industry, Incidence (epidemiology), Stimulation, Day care, Double blind, Clinical trial, Infectious Diseases, El Niño, Internal medicine, Pediatrics, Perinatology and Child Health, Immunology, medicine, business
Abstract

A randomized, double blind, placebo-controlled clinical trial was performed in 423 children attending day-care centers to assess whether stimulating nonspecific immunity would reduce the incidence of recurrent infections. The drug used for the trial (Imocur®) is an extract obtained from eight differ

Published
1993

26. Type of Day-Care Setting and Risk of Repeated Infections

Author

Daniel Floret, Michael S. Kramer, N. Bossard, P Burtin, T Ducruet, and Collet Jp

Subjects
Pediatrics, medicine.medical_specialty, Respiratory tract infections, business.industry, Risk of infection, Attendance, Day care, medicine.disease, Upper respiratory tract infection, Otitis, Pediatrics, Perinatology and Child Health, medicine, Risk factor, medicine.symptom, business, Developed country
Abstract

As a direct result of demographic and sociologic changes, increasing numbers of children are attending day care in all industrialized countries. Unfortunately, the close physical contact among children in day care favors the transmission of infectious diseases. Previous studies have focused mainly on the risk of upper respiratory tract infection (URTI) and otitis media, which are reported to occur two to three times more frequently in children attending day care centers than in those cared for at home.1-7 Similarly day-care attendance has been found to be associated with an increased risk of lower respiratory tract infections (LRTI),8 gastroenteritis,9 as well as with the dissemination of infections caused by hepatitis A,10 cytomegalovirus,11 and H. influenzae type b.12 Despite convincing evidence for a higher risk of infection in day-care centers, most parents do not have an acceptable alternative to day care. It may be more useful, therefore, to identify the types of day-care structures associated with lower infectious risks. Family day care, in which several children are cared for in another family setting, offers a viable alternative to group day care, but previous studies have provided conflicting information on the risk of respiratory infections and otitis media in this setting. In four studies, the risks observed in family day care were very close to those of children who remained at home3-5,8; in two, they were intermediate between the risks at home and those in formal day-care centers6,7; while in two others, they were very close to those in day-care centers.13 These conflicting results can be explained by several factors including the lack of strict definitions for the different types of day-care settings and failure to control for the potentially important confounding differences in the number of children attending each type, the age range (from 2 to 60 months), and the time per week spent in the setting.

Published
1994

27. Drug prescription in young children: results of a survey in France

Author

D. Honegger, Jean-Pierre Boissel, D. Floret, N. Bossard, Collet Jp, and J. Gillet

Subjects
Pharmacology, Drug Utilization, Drug, Pediatrics, medicine.medical_specialty, business.industry, medicine.drug_class, Incidence (epidemiology), media_common.quotation_subject, Antibiotics, General Medicine, Day care, El Niño, Medicine, Pharmacology (medical), Medical prescription, business, Prospective cohort study, media_common
Abstract

A 8.5-month prospective study was performed in the Rhone area of France to study the incidence of infectious diseases in children in day care, and the qualitative and quantitative aspects of drug prescriptions for young children. The families of 1.359 children agreed to participate (98.5% of those selected). During the follow-up period 3.605 infections episodes were reported and 10.706 medications were used, an average of 3.0 medications per episode. Antibiotics were used in the treatment of 2.333 infectious episodes (65%) amoxycillin (36%), cephalosporin (23%), macrolide (17%) and trimethoprim-sulphamethoxazole (9%). Acetylsalicylic acid and paracetamol were used 865- and 1.568-times, respectively. Drugs with multi-active components represented 11.3% of the total number of systemic medicines reported. Paracetamol was prescribed in 59% of cases in a multi-active component drug, whereas this type of product accounted for 83.5% of the antihistamines (used 932-times). The rationale behind the paediatric prescribing habits of French medical doctors is discussed in relation to results previously obtained in other European countries.

Published
1991

28. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study

Author

Wykrzykowska, Joanna, Warnholtz, A, de Jaeger, P, Curzen, N, Oldroyd, KG, Collet, JP, van den Berg, JM, Rademaker, T, Goedhart, D, Lissens, J, Kint, PP, Serruys, PWJC (Patrick), Wykrzykowska, Joanna, Warnholtz, A, de Jaeger, P, Curzen, N, Oldroyd, KG, Collet, JP, van den Berg, JM, Rademaker, T, Goedhart, D, Lissens, J, Kint, PP, and Serruys, PWJC (Patrick)

Abstract

Antiplatelet therapy with clopidogrel has been shown to reduce major adverse cardiac events in acute coronary syndromes and after percutaneous interventions. This effect is not only due to its anti-platelet effect but also possibly due to an anti-inflammatory effect. The effect of clopidogrel cessation after one year of therapy on markers of inflammation has been investigated in diabetics and showed an increase in platelet aggregation as well as hsCRP and surface P-selectin levels. This was an exploratory multicenter prospective open-label single arm study of 98 non-diabetic patients who had received one or more drug eluting stents and were coming to the end of their 12 months course of clopidogrel therapy. The effect of clopidogrel cessation on expression of biomarkers: sCD40L, soluble P-selectin and hsCRP was measured right before clopidogrel cessation ( day 0), and subsequently at 1, 2, 3 and 4 weeks after drug withdrawal. A median increase in sCD40L expression from 224 to 324.5 pg/ml was observed between baseline and 4 weeks after clopidogrel cessation, which corresponded to a 39% mean percent change based on an ANCOVA model (P < 0.001). Over the 4 weeks observation period the change in sCD40L expression correlated weakly with soluble P-selectin levels ( at 4 weeks Spearman's correlation coefficient = 0.32; P = 0.0024). Increase in P-selectin expression from baseline was statistically significant at week 1 and 2. Conversely, hsCRP level decreased by 21% at 1 week ( P = 0.008) and was still reduced by 18% by 4 weeks ( P = 0.062). The change in sCD40L expression appeared to vary with the type of drug eluting stent. Patients treated with drug eluting stents at 1 year after implantation display significant increase in sCD40L and decrease in hsCRP after clopidogrel cessation. Further studies should elucidate if this increase in sCD40L levels reflects solely the removal of the inhibitory effects of clopidogrel on platelet activity or rather an increase in pro

Published
2009

35. REDUCTION OF HOSPITAL UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A DISEASE-SPECIFIC SELF-MANAGEMENT INTERVENTION

Author

Bourbeau, J, primary, Julien, M, additional, Maltais, F, additional, Rouleau, M, additional, Beaupre, A, additional, Begin, R, additional, Renzi, P, additional, Nault, D, additional, Borycki, E, additional, Schwartzman, K, additional, Singh, R, additional, Collet, JP, additional, Tiukinhoy, Susan, additional, and Rochester, Carolyn, additional

Published
2004
Full Text
View/download PDF

37. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Author

Bellemain-Appaix A, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet JP, Jacq L, Bernasconi F, Montalescot G, ACTION Group, Bellemain-Appaix, Anne, O'Connor, Stephen A, Silvain, Johanne, Cucherat, Michel, Beygui, Farzin, Barthélémy, Olivier, Collet, Jean-Philippe, Jacq, Laurent, and Bernasconi, François

Abstract

Context: Clopidogrel pretreatment is recommended for patients with acute coronary syndromes (ACS) and stable coronary artery disease who are scheduled for percutaneous coronary intervention (PCI), but whether using clopidogrel as a pretreatment for PCI is associated with positive clinical outcomes has not been established.Objective: To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI.Data Sources: MEDLINE, EMBASE, Cochrane Controlled Trials Register databases, and reference lists of qualifying articles. STUDY SELECTION Studies reporting clinical data on mortality and major bleeding were included. Of the 392 titles identified, 15 articles published between August 2001 and September 2012 met the inclusion criteria: 6 randomized controlled trials (RCTs), 2 observational analyses of RCTs, and 7 observational studies.Data Extraction: Quality of studies was assessed with the Ottawa Scale and the Jadad Score as appropriate. Results were independently extracted by 2 reviewers. A random-effect model was applied. Pretreatment was defined as the administration of clopidogrel before PCI or catheterization. The main analysis was performed on RCTs and confirmed by observational analyses and observational studies. Prespecified subgroups--clinical presentation and clopidogrel loading dose--were analyzed. The primary efficacy and safety end points were all-cause mortality and major bleeding. Secondary end points included major cardiac events.Results: Of the 37 814 patients included in the meta-analysis, 8608 patients had participated in RCTs; 10,945, in observational analyses of RCTs; and 18,261, in observational studies. Analysis of RCTs showed that clopidogrel pretreatment was not associated with a reduction of death (absolute risk, 1.54% vs 1.97%; OR, 0.80; 95% CI, 0.57-1.11; P = .17) but was associated with a lower risk of major cardiac events (9.83% vs 12.35%; OR, 0 .77; 95% CI, 0.66-0.89; P < .001). There was no significant association between pretreatment and major bleeding overall (3 .57% vs 3.08%; OR, 1.18; 95% CI, 0.93-1.50; P = .18). Analyses from observational analyses of RCTs and observational studies were consistent for all results.Conclusions: Among patients scheduled for PCI, clopidogrel pretreatment was not associated with a lower risk of mortality but was associated with a lower risk of major coronary events. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

40. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.

Author

Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, Choussat R, Leclercq F, Silvain J, Duclos F, Aout M, Dubois-Randé JL, Barthélémy O, Ducrocq G, Bellemain-Appaix A, Payot L, Steg PG, Henry P, Spaulding C, and Vicaut E

Abstract

Context: International guidelines recommend an early invasive strategy for patients with high-risk acute coronary syndromes without ST-segment elevation, but the optimal timing of intervention is uncertain.Objective: To determine whether immediate intervention on admission can result in a reduction of myocardial infarction compared with a delayed intervention.Design, Setting, and Patients: The Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention (ABOARD) study, a randomized clinical trial that assigned, from August 2006 through September 2008 at 13 centers in France, 352 patients with acute coronary syndromes without ST-segment elevation and a Thrombolysis in Myocardial Infarction (TIMI) score of 3 or more to receive intervention either immediately or on the next working day (between 8 and 60 hours after enrollment).Main Outcome Measures: The primary end point was the peak troponin value during hospitalization; the key secondary end point was the composite of death, myocardial infarction, or urgent revascularization at 1-month follow-up.Results: Time from randomization to sheath insertion was 70 minutes with immediate intervention vs 21 hours with delayed intervention. The primary end point did not differ between the 2 strategies (median [interquartile range] troponin I value, 2.1 [0.3-7.1] ng/mL vs 1.7 [0.3-7.2] ng/mL in the immediate and delayed intervention groups, respectively; P = .70). The key secondary end point was observed in 13.7% (95% confidence interval, 8.6%-18.8%) of the group assigned to receive immediate intervention and 10.2% (95% confidence interval, 5.7%-14.6%) of the group assigned to receive delayed intervention (P = .31). The other end points, as well as major bleeding, did not differ between the 2 strategies.Conclusion: In patients with acute coronary syndromes without ST-segment elevation, a strategy of immediate intervention compared with a strategy of intervention deferred to the next working day (mean, 21 hours) did not result in a difference in myocardial infarction as defined by peak troponin level.Trial Registration: clinicaltrials.gov Identifier: NCT00442949. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

41. Can we override clopidogrel resistance?

Author

Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, Funck-Brentano C, Montalescot G, Pena, Ana, Collet, Jean-Philippe, Hulot, Jean-Sébastien, Silvain, Johanne, Barthélémy, Olivier, Beygui, Farzin, Funck-Brentano, Christian, and Montalescot, Gilles

Published
2009
Full Text
View/download PDF

42. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations.

Author

Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, Wang C, and Bourbeau J

Abstract

RATIONALE: Depression and anxiety are significant comorbid and potentially modifiable conditions in chronic obstructive pulmonary disease (COPD), but their effects on exacerbations are not clear. OBJECTIVES: To investigate the independent effect of depression and anxiety on the risk of COPD exacerbations and hospitalizations. METHODS: A multicenter prospective cohort study in 491 patients with stable COPD in China. Multivariate Poisson and linear regression analyses were used, respectively, to estimate adjusted incidence rate ratios (IRRs) and adjusted effects on duration of events. MEASUREMENTS AND MAIN RESULTS: Depression and anxiety were measured using the Hospital Anxiety and Depression Scale (HADS) at baseline. Other measurements included sociodemographic, clinical, psychosocial, and treatment characteristics. Patients were then monitored monthly for 12 months to document the occurrence and characteristics of COPD exacerbations and hospitalizations. Exacerbation was determined using both symptom-based (worsening of > or =1 key symptom) and event-based definitions (> or =1 symptom worsening plus > or =1 change in regular medications). A total of 876 symptom-based and 450 event-based exacerbations were recorded, among which 183 led to hospitalization. Probable depression (HADS depression score > or = 11) was associated with an increased risk of symptom-based exacerbations (adjusted IRR, 1.51; 95% confidence interval [CI], 1.01-2.24), event-based exacerbations (adjusted IRR, 1.56; 95% CI, 1.02-2.40), and hospitalization (adjusted IRR, 1.72; 95% CI, 1.04-2.85) compared with nondepression (score < or = 7). The duration of event-based exacerbations was 1.92 (1.04-3.54) times longer for patients with probable anxiety (HADS anxiety score > or = 11) than those with no anxiety (score < or = 7). CONCLUSIONS: This study suggests a possible causal effect of depression on COPD exacerbations and hospitalizations. Further studies are warranted to confirm this finding and to test the effectiveness of antidepressants and psychotherapies on reducing exacerbations and improving health resource utilizations. [ABSTRACT FROM AUTHOR]

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results